tbuckley/cabot-search huggingface dataset:
Association of Angiotensin II Type 1 Receptor Agonistic Autoantibodies With Outcomes in Patients With Acute Aortic Dissection
Authors: Xiao-wei Wu, Gang Li, Xiao-bin Cheng, Min Wang, Liu-lin Wang, Hai-hao Wang, Jian-ye Yang, Xing-jian Hu
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Angiotensin II is significantly associated with the pathogenesis of acute aortic dissection. Angiotensin II type 1 receptor agonistic autoantibodies (AT1-AAs) can mimic the effect of angiotensin II. <h3>Objective</h3> To investigate the association between AT1-AAs and all-cause and cause-specific mortality risk in patients with acute aortic dissection. <h3>Design, Setting, and Participants</h3> A total of 662 patients with clinically suspected aortic dissection from 3 medical centers in Wuhan, China, were enrolled in this cohort study from August 1, 2014, to July 31, 2016. Of these, 315 patients were included in the 3-year follow-up study. Follow-up was mainly performed via telephone interviews and outpatient clinic visits. Data analysis was conducted from March 1 to May 31, 2020. <h3>Main Outcomes and Measures</h3> The primary outcomes of interest were all-cause mortality, death due to aortic dissection, and late aortic-related adverse events. <h3>Results</h3> The full study cohort included 315 patients with AAD (mean [SD] age, 56.2 [12.7] years; 230 men [73.0%]). Ninety-two patients (29.2%) were positive for AT1-AAs. The mortality of AT1-AA–positive patients was significantly higher than that of AT1-AA–negative patients (40 [43.5%] vs 37 [16.6%];<i>P</i> &lt; .001). The mortality risk in AT1-AA–positive patients was always significantly higher than that in AT1-AA–negative patients in patients with both type A and type B dissection. Multivariable analysis showed that the risk of AT1-AA–positive patients for type A dissection was significantly higher than that of AT1-AA–negative patients (odds ratio [OR], 1.88; 95% CI, 1.12-3.13;<i>P</i> = .02). The Cox proportional hazards regression model showed a significant increase of all-cause mortality risk (OR, 2.27; 95% CI, 1.44-3.57;<i>P</i> &lt; .001) and late aortic-related adverse events (OR, 1.58; 95% CI, 1.06-2.36;<i>P</i> = .03) among AT1-AA–positive patients during the follow-up period compared with AT1-AA–negative patients. <h3>Conclusions and Relevance</h3> This cohort study first detected AT1-AAs in patients with acute aortic dissection. The presence of AT1-AAs was associated with significantly higher all-cause and cause-specific mortality during a follow-up period of 3 years. The antibodies may be a risk factor for aortic dissection.
1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
Authors: D. Arnold, T. Golan, P. Hammel, M. Reni, E. Van Cutsem, T. Macarulla Mercade, M.J. Hall, J.O. Park, D. Hochhauser, D-Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E.M. O'Reilly, S. Bordia, D. McGuinness, K.Y. Cui, G. Locker, H. Kindler
Journal: Annals of Oncology (2021)
Medical students skipped training placements and stayed up overnight to book exam slot
Authors: Pat Lok
Journal: BMJ (2021)

Problems with the online booking system for a compulsory exam have caused significant disruption for medical students for the second year in a row.1

The situational judgement test is a compulsory examination for entry to the UK foundation programme, designed to test the attributes needed to work as a foundation doctor. It accounts for 50% of a student’s foundation programme application score.

This year, for the second year in a row, medical students will sit the exam at Pearson VUE testing centres rather than at their university. Booking an exam slot at one of these centres operates online on a first come, first served basis, and students are advised to …
49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
Authors: N-J. Chiang, L-Y. Bai, C-J. Huang, S-C. Chen, C-F. Hsiao, Y-S. Shan, Y-Y. Su, L. Chen, M-H. Chen
Journal: Annals of Oncology (2021)
Is It Ethical to Mandate SARS-CoV-2 Vaccinations among Incarcerated Persons?
Authors: Lao-Tzu Allan-Blitz
Journal: The American Journal of Bioethics (2021)

Click to increase image sizeClick to decrease image sizeThis article is referred to by:Is It Ethical to Mandate Vaccination among Incarcerated Persons? Consider Enforcement and Ask People Living in Prisons and Jails DISCLOSURE STATEMENTThe author has served as a consultant for Curative Inc. There was no funding for this piece.Notes1 Excluding 33,191,495 living individuals with prior SARS-CoV-2 infection and 160,090,0003 fully vaccinated individuals (Centers for Disease Control and Prevention 2021), an estimated 42% of the general population (conservatively) remains susceptible to SARS-CoV-2.
Alopecia areata: progress, but who pays?
Authors: R. Sinclair
Journal: British Journal of Dermatology (2021)

Alopecia areata: progress, but who pays?Alopecia areata (AA) is common.It might be the most common autoimmune disease in humans.With Janus kinase inhibitors (JAKi) emerging as the first disease-specific, systemic immunotherapy for AA, 1,2 funding bodies will want to know just how common AA is in the UK.
387MO Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial
Authors: H. Blons, V. Polivka, E. Francois, M. Ben Abdelghani, J.M. Phelip, V. Lebrun-Ly, L. Mineur, S. Garinet, F.F. Farace, N. Lachaux, S. Gourgou, O. Bouche, V. Boige
Journal: Annals of Oncology (2021)
1062P Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands
Authors: M.W. Rohaan, M.L. Duizer, L.A. Devriese, S. Wilgenhof, C.M. Van Herpen, J.B.A.G. Haanen
Journal: Annals of Oncology (2021)
704P Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
Authors: A.K. Morgans, M.D. Galsky, Z. Hepp, N.N. Chang, M. Campbell, H.S. Wirtz, R. Fuldeore, S. Sesterhenn, A. Surinach, Y. Liu, G.P. Sonpavde
Journal: Annals of Oncology (2021)
570P Retrospective analysis of PDL-1, LAG3, TIM3, OX40L and MSI status in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Authors: F. Gurler, S. Aktürk Esen, B. Kurt İnci, O. Sutcuoglu, G. Uçar, D. Uncu, N. Turhan, N. Akyurek, N. Özdemir, A. Özet, O. Yazıcı
Journal: Annals of Oncology (2021)
Association of Childhood Adversity With Morbidity and Mortality in US Adults
Authors: Lucinda Rachel Grummitt, Noah T. Kreski, Stephanie Gyuri Kim, Jonathan Platt, Katherine M. Keyes, Katie A. McLaughlin
Journal: JAMA Pediatrics (2021)

Childhood adversity (CA) is a powerful determinant of long-term physical and mental health that is associated with elevated risk for chronic disease and psychopathology. However, the degree to which CA contributes to mortality as a preventable driver of ill-health and death is unknown.To estimate the contribution of CA to health behaviors, including smoking and sedentary behavior, as well as the annual mortality attributable to CA in the US through influences on leading causes of death (eg, cardiovascular disease).For this systematic review, the PsycINFO and MEDLINE databases were searched on November 15, 2019. The databases were searched for publications from inception (1806 for PsycINFO, 1946 for MEDLINE) to November 15, 2019. Meta-analyses of the associations between CA and morbidity outcomes were included. The population attributable fraction (PAF) was calculated from these associations along with the estimated US prevalence of CA. The PAF was then applied to the number of annual deaths associated with each cause of death to estimate the number of deaths that are attributable to CA. Additionally, the PAF was applied to the incidence of health behaviors to derive the number of cases attributable to CA. Exposure to 1 or more experiences of adversity before the age of 18 years was analyzed, including abuse, neglect, family violence, and economic adversity.A total of 19 meta-analyses with 20 654 832 participants were reviewed. Childhood adversity accounted for approximately 439 072 deaths annually in the US, or 15% of the total US mortality in 2019 (2 854 838 deaths), through associations with leading causes of death (including heart disease, cancer, and suicide). In addition, CA was associated with millions of cases of unhealthy behaviors and disease markers, including more than 22 million cases of sexually transmitted infections, 21 million cases of illicit drug use, 19 million cases of elevated inflammation, and more than 10 million cases each of smoking and physical inactivity. The greatest proportion of outcomes attributable to CA were for suicide attempts and sexually transmitted infections, for which adversity accounted for up to 38% and 33%, respectively.The results of this systematic review suggest that CA is a leading contributor to morbidity and mortality in the US and may be considered a preventable determinant of mortality. The prevention of CA and the intervention on pathways that link these experiences to elevated disease risk should be considered a critical public health priority.
Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis
Authors: Xueyu Wang, Zhiqiang Wei, Bin Cheng, Jia Li, Yulin He, Tingyu Lan, Thekla Kemper, Yong Lin, Bin Jiang, Yongfang Jiang, Zhongji Meng, Mengji Lu
Journal: Hepatology (2021)

HBV infection has been reported to trigger endoplasmic reticulum (ER) stress and initiate autophagy. However, how ER stress and autophagy influence HBV production remains elusive. Here, we studied the effect of tunicamycin (TM), an N-glycosylation inhibitor and ER stress inducer, on HBV replication and secretion and examined the underlying mechanisms.Protein disulfide isomerase (an ER marker), microtubule-associated protein 1 light chain 3 beta (an autophagosome [AP] marker), and sequestosome-1 (a typical cargo for autophagic degradation) expression were tested in liver tissues of patients with chronic HBV infection and hepatoma cell lines. The role of TM treatment in HBV production and trafficking was examined in hepatoma cell lines. TM treatment that mimics HBV infection triggered ER stress and increased AP formation, resulting in enhanced HBV replication and secretion of subviral particles (SVPs) and naked capsids. Additionally, TM reduced the number of early endosomes and HBsAg localization in this compartment, causing HBsAg/SVPs to accumulate in the ER. Thus, TM-induced AP formation serves as an alternative pathway for HBsAg/SVP trafficking. Importantly, TM inhibited AP-lysosome fusion, accompanied by enhanced AP/late endosome (LE)/multivesicular body fusion, to release HBsAg/SVPs through, or along with, exosome release. Notably, TM treatment inhibited HBsAg glycosylation, resulting in impairment of HBV virions' envelopment and secretion, but it was not critical for HBsAg/SVP trafficking in our cell systems.TM-induced ER stress and autophagic flux promoted HBV replication and the release of SVPs and naked capsids through the AP-LE/MVB axis.
Reed Elsevier and the arms trade revisited
Authors: Arturo Quizphe, Alexis Benos, Bridget Lloyd, Ravi Narayan, Claudio Schuftan, David McCoy, Delen de la Paz, David Legge, Jihad Mashal, Lanny Smith, Maija Kagis, Ghassan Issa, Fran Baum, Alaa Shukrallah, Hani Serag, Prem John, Zafrullah Chowdury, David Sanders, Sarah Shannon, Khor Kok Peng
Journal: The Lancet (2007)
Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin
Authors: Jung Seok Lee, Patrick Han, Rabib Chaudhury, Shihan Khan, Sean Bickerton, Michael D. McHugh, Hyun Bong Park, Alyssa L. Siefert, Gerald Rea, José M. Carballido, David A. Horwitz, Jason Criscione, Karlo Perica, Robert Samstein, Ragy Ragheb, Dongin Kim, Tarek M. Fahmy
Journal: Nature Biomedical Engineering (2021)
580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity
Authors: N. Mehra, J. de Bono, A.D. Laird, P. Barthélémy, R. Delva, T. Dorff, M. Maruzzo, A. Stirling, J-P. Machiels, H. Dumez, V. Renard, J. Hopkins, L.A. Albacker, H-C. Chen, C. Healy, J. Chelliserry, I.M. van Oort, G. Scagliotti, K. Fizazi
Journal: Annals of Oncology (2021)
Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis
Authors: Zhijun Liu, Yuyu You, Qiyi Chen, Guobang Li, Wenfeng Pan, Qing Yang, Jiajun Dong, Yi Wu, Jin-Xin Bei, Chaoyun Pan, Fuming Li, Bo Li
Journal: Molecular Therapy (2021)

Hepatocellular carcinoma (HCC) is frequently characterized by metabolic and immune remodeling in the tumor microenvironment. We previously discovered that liver-specific deletion of fructose-1, 6-bisphosphatase 1 (FBP1), a gluconeogenic enzyme ubiquitously suppressed in HCC tissues, promotes liver tumorigenesis and induces metabolic and immune perturbations closely resembling human HCC. However, the underlying mechanisms remain incompletely understood. Here, we reported that FBP1-deficient livers exhibit diminished amounts of natural killer (NK) cells and accelerated tumorigenesis. Using the diethylnitrosamine-induced HCC mouse model, we analyzed potential changes in the immune cell populations purified from control and FBP1-depleted livers and found that NK cells were strongly suppressed. Mechanistically, FBP1 attenuation in hepatocytes derepresses an zeste homolog 2 (EZH2)-dependent transcriptional program to inhibit PKLR expression. This leads to reduced levels of PKLR cargo proteins sorted into hepatocyte-derived extracellular vesicles (EVs), dampened activity of EV-targeted NK cells, and accelerated liver tumorigenesis. Our study demonstrated that hepatic FBP1 depletion promotes HCC-associated immune remodeling, partly through the transfer of hepatocyte-secreted, PKLR-attenuated EVs to NK cells. Hepatocellular carcinoma (HCC) is frequently characterized by metabolic and immune remodeling in the tumor microenvironment. We previously discovered that liver-specific deletion of fructose-1, 6-bisphosphatase 1 (FBP1), a gluconeogenic enzyme ubiquitously suppressed in HCC tissues, promotes liver tumorigenesis and induces metabolic and immune perturbations closely resembling human HCC. However, the underlying mechanisms remain incompletely understood. Here, we reported that FBP1-deficient livers exhibit diminished amounts of natural killer (NK) cells and accelerated tumorigenesis. Using the diethylnitrosamine-induced HCC mouse model, we analyzed potential changes in the immune cell populations purified from control and FBP1-depleted livers and found that NK cells were strongly suppressed. Mechanistically, FBP1 attenuation in hepatocytes derepresses an zeste homolog 2 (EZH2)-dependent transcriptional program to inhibit PKLR expression. This leads to reduced levels of PKLR cargo proteins sorted into hepatocyte-derived extracellular vesicles (EVs), dampened activity of EV-targeted NK cells, and accelerated liver tumorigenesis. Our study demonstrated that hepatic FBP1 depletion promotes HCC-associated immune remodeling, partly through the transfer of hepatocyte-secreted, PKLR-attenuated EVs to NK cells.
Evaluation of portable devices for medicine quality screening: Lessons learnt, recommendations for implementation, and future priorities
Authors: Céline Caillet, Serena Vickers, Vayouly Vidhamaly, Kem Boutsamay, Phonepasith Boupha, Stephen Zambrzycki, Nantasit Luangasanatip, Yoel Lubell, Facundo M. Fernández, Paul N. Newton
Journal: PLoS Medicine (2021)

Portable devices able to detect substandard and falsified medicines are vital innovations for enhancing the inspection of medicines in pharmaceutical supply chains and for timely action before they reach patients.Such devices exist, but there has been little to no independent scientific evidence of their accuracy and cost-effectiveness to guide regulatory authorities in choosing appropriate devices for their settings.• We tested 12 portable devices, evaluated their diagnostic performances and the resources required to use each device in a laboratory.• We then assessed the utility and usability of the devices in medicine inspectors' hands in a pharmacy mimicking a real-life Lao pharmacy.• We then assessed the health and economic benefits of using portable devices compared to not using them in a low-to middle-income setting.• Here, we discuss the conclusions and practical implications of the multiphase study discussed in this Collection.We discuss the results, highlight the evidence gaps, and provide recommendations on the key aspects to consider in the implementation of portable devices and their main advantages and limitations.
1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
Authors: C. Le Pechoux, F. Barlesi, N. Pourel, C. Faivre-Finn, D. Lerouge, G. Zalcman, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, F. Thillays, A. Paumier, E. Dansin, K. Peignaux, J. Madelaine, E. Pichon, A. Larrouy, O. Riesterer, A. Lavolle, A. Bardet
Journal: Annals of Oncology (2021)
564TiP A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer
Authors: G.P. Keogh, S. Papish, W. Piskorski, M. Ulanska, B. Jackson, M. Suster, M. Ptaszynski, L. Mina
Journal: Annals of Oncology (2021)
574P Clinical impact of the GAPP score and SDHB negativity in patients with pheochromocytoma/paraganglioma
Authors: A. Ohmoto, Y. Shigematsu, Y. Fujiwara, J. Tomomatsu, T. Yuasa, J. Yonese, K. Inamura, S. Takahashi
Journal: Annals of Oncology (2021)
244P Real-world first-line treatment patterns and outcomes in hormone-receptor positive advanced breast cancer patients: A multicenter, retrospective study
Authors: Z. Chen, X. Wang, Q. Ouyang, C. Tian, Y. Wang, H. Wang, J. Wang, H. Liang, C. Wang, X. Wu, Y. Zhang, P. Zhang, D. Ren, J. Huang, Y. Zheng, W. Cao, X. Shao
Journal: Annals of Oncology (2021)
821TiP GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study
Authors: T. De La Motte Rouge, D. Berton, E. Kalbacher, B. Asselain, O. Collard, M. Rodrigues, L. Bengrine Lefevre, E. Rouleau, C. Nogues, P.A. Just, A. Morel, V. Verriele, R. Boidot, L. Arnould, A. Buisson, I. Treilleux, C. Callens, G. Bataillon, V. Becette, E. Pujade-Lauraine
Journal: Annals of Oncology (2021)
854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Authors: M.M. Patnaik, M.A. Sekeres, A. DeZern, S. Luger, L. Sproat, R. Bejar, G. Hobbs, G.J. Roboz, M. Leoni, B. Martell, E. Padron
Journal: Annals of Oncology (2021)
1003P Expression by immunohistochemistry of p53 tumor suppressor protein as a predictive biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer
Authors: A. Olivares Hernandez, E. del Barco, L. Figuero Pérez, R.A. Escala Cornejo, M.C. Parra Pérez, A. Rodrigues Françoso, L. Bellido Hernández, R. Vidal Tocino, E. Escalera Martín, J. Claros Ampuero, E. Terán Brage, Á. López Gutiérrez, M.D. Ludeña de la Cruz, J.J. Cruz-Hernández
Journal: Annals of Oncology (2021)
579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Authors: D.P. Petrylak, J.L. Perez-Gracia, L. Lacombe, D.A. Bastos, H. Mahammedi, E.M. Kwan, S. Zschäbitz, A.J. Armstrong, R.K. Pachynski, J.C. Goh, M. Burotto, G. Gravis, S.L. McCune, J.C. Vázquez Limón, M. Retz, F. Saad, N.P. Amin, J. Li, K. Unsal-Kacmaz, K. Fizazi
Journal: Annals of Oncology (2021)
1603P SARS-CoV-2 seroconversion among oncology healthcare workers in Brazil
Authors: C. Ismael, P.A. Ismael Amaral Silva, C. Marchon da Silva, M.S. Vieira de Melo, B. Ferreira Neto, R. Macario, J. Vieira de Melo, V. Agibert, C. Domenge
Journal: Annals of Oncology (2021)
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Authors: Richard A Furie, Gustavo Aroca, Matthew D Cascino, Jay P Garg, Brad H Rovin, Analia Alvarez, Hilda Fragoso-Loyo, Elizabeth Zuta-Santillan, Thomas Schindler, Paul Brunetta, Cary M Looney, Imran Hassan, Ana Malvar
Journal: Annals of the Rheumatic Diseases (2021)

Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN in combination with standard therapies.Patients with LN receiving mycophenolate and corticosteroids were randomised to obinutuzumab 1000 mg or placebo on day 1 and weeks 2, 24 and 26, and followed through week 104. The primary endpoint was complete renal response (CRR) at week 52. Exploratory analyses through week 104 were conducted. The prespecified alpha level was 0.2.A total of 125 patients were randomised and received blinded infusions. Achievement of CRR was greater with obinutuzumab at week 52 (primary endpoint, 22 (35%) vs 14 (23%) with placebo; percentage difference, 12% (95% CI -3.4% to 28%), p=0.115) and at week 104 (26 (41%) vs 14 (23%); percentage difference, 19% (95% CI 2.7% to 35%), p=0.026). Improvements in other renal response measures, serologies, estimated glomerular filtration rate and proteinuria were greater with obinutuzumab. Obinutuzumab was not associated with increases in serious adverse events, serious infections or deaths. Non-serious infusion-related reactions occurred more frequently with obinutuzumab.Improved renal responses through week 104 were observed in patients with LN who received obinutuzumab plus standard therapies compared with standard therapies alone. Obinutuzumab was well tolerated and no new safety signals were identified.NCT02550652.
1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre
Authors: S. Dolly, B. Russell, C.L. Moss, E. Tsotra, C. Gousis, J. Roca, A. Sita-Lumsden, M. Khan, D. Josephs, K. Zaki, D. Smith, V. Michalarea, R. Kristeleit, D. Enting, L. Flanders, M. Lei, E. Sawyer, J. Spicer, P. Ross, A. Montes, M. Van Hemelrijick
Journal: Annals of Oncology (2021)
1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Authors: J. Martin Broto, C. Valverde, N. Hindi, B. Vincenzi, J. Martinez-Trufero, G. Grignani, A. Italiano, J. Lavernia, R. Gonzalez-Campora, A. Vallejo, D. Hernandez-Jover, A. Gutierrez, C. Serrano, D. Moura, J.A. Lopez-Guerrero, J. Cruz, A. Fernández-Serra, J-Y. Blay, E.R. Fumagalli, V. Martinez Marin
Journal: Annals of Oncology (2021)
703P Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Authors: N. Xing, S. Han, J. Jiang, W. Xu, B. Shi, H. Ping, Z. Ji, Q. Ma, H. Wang, S. Chen, W. Wang, X. Fan, Q. Zhou, W. Zhang
Journal: Annals of Oncology (2021)
726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
Authors: N. Colombo, D. Lorusso, A. Casado Herráez, A.D. Santin, E. Colomba, D.S. Miller, K. Fujiwara, S. Pignata, A. Floquet, B.J. Monk, S. Banerjee, R.T. Penson, R. Kristeleit, M. Fabbro, M. Orlando, H. Mackay, E. Jensen, L. Dutta, R. Orlowski, V. Makker
Journal: Annals of Oncology (2021)